Scrip Reports - Drug Delivery Companies Fact File

Scrip's Drug Delivery Companies Fact File – 1st Edition

Reference

Drug delivery is one of the fastest growing divisions in the healthcare industry. There are great opportunities for companies investing in R&D for new, improved drug administration systems, allowing for improved therapeutic absorption and efficacy in patients.

This reference source contains in-depth information on over 100 of the top players in drug delivery and on their major technology platforms, providing all the information YOU need to tap into this expanding market.

Profiles of the top companies include: Company description, address and contact details
Financial summaries for the past 3 years
Key information on marketed drug delivery technologies
Patent status information on launched products
Details of R&D drug delivery pipelines
Description of leading marketed products
Collaborations and licensing agreements
Details of senior executives and licensing contact/s

The up-to-date, extensively researched information included in Scrip's Drug Delivery Fact File will enable you to:

Access information on new, improved drug delivery technologies
Identify new licensing opportunities and potential partners
Evaluate your major competitors
Discover opportunities for the development of your own, improved drug delivery technologies

PUBLISHED: October 2000
REF: BS1072E
PAGES: 300
PRICE: £750/$1,575/¥180,000

CONTENTS
FOREWORD
REFERENCES
GLOSSARY AND ABBREVIATIONS

PROFILE 1 3M DRUG DELIVERY SYSTEMS
PROFILE 2 ADD ADVANCED DRUG DELIVERY TECHNOLOGIES LTD
PROFILE 3 ADVANCED POLYMER SYSTEMS
PROFILE 4 AEROGEN
PROFILE 5 ALKERMES
PROFILE 6 ALZA
PROFILE 7 AMARIN
PROFILE 8 ANDRX
PROFILE 9 ANESTA
PROFILE 10 APPLIED PHARMA RESEARCH
PROFILE 11 ARADIGM CORPORATION
PROFILE 12 ARONEX PHARMACEUTICALS
PROFILE 13 Atrix Laboratories
PROFILE 14 BENTLEY PHARMACEUTICALS
PROFILE 15 BIOGLAN
PROFILE 16 BIOJECT MEDICAL TECHNOLOGIES
PROFILE 17 Biosyn
PROFILE 18 Biovail
PROFILE 19 BIOVECTOR THERAPEUTICS
PROFILE 20 BRADFORD PARTICLE DESIGN
PROFILE 21 CENES PHARMACEUTICALS
PROFILE 22 CIMA LABS
PROFILE 23 COLUMBIA LABORATORIES
PROFILE 24 CONTROLLED THERAPEUTICS
PROFILE 25 CyDex
PROFILE 26 DEBIO GROUP
PROFILE 27 DepoMed
PROFILE 28 DIMETHAID
PROFILE 29 Direct-Haler
PROFILE 30 D-Pharm
PROFILE 31 DURA PHARMACEUTICALS
PROFILE 32 ELAN
PROFILE 33 EMISPHERE TECHNOLOGIES
PROFILE 34 ENZON
PROFILE 35 Ethypharm
PROFILE 36 EURAND
PROFILE 37 FLAMEL TECHNOLOGIES
PROFILE 38 FLEMINGTON PHARMACEUTICAL
PROFILE 39 FOCAL
PROFILE 40 FOUNTAIN PHARMACEUTICALS
PROFILE 41 FRESENIUS KABI
PROFILE 42 GELKEM
PROFILE 43 GELTEX
PROFILE 44 Generex
PROFILE 45 GENETRONICS BIOMEDICAL
PROFILE 46 GILEAD SCIENCES
PROFILE 47 GUILFORD PHARMACEUTICALS
PROFILE 48 HELIX BIOPHARMA
PROFILE 49 IDEA
PROFILE 50 INEX PHARMACEUTICALS
PROFILE 51 INHALE THERAPEUTIC SYSTEMS
PROFILE 52 IOMAI
PROFILE 53 IOMED
PROFILE 54 KOS PHARMACEUTICALS
PROFILE 55 KV PHARMACEUTICAL
PROFILE 56 LABOPHARM
PROFILE 57 LecTec
PROFILE 58 Lipoxen
PROFILE 59 MacroChem
PROFILE 60 MATRIX PHARMACEUTICAL
PROFILE 61 MEDI-JECT CORPORATION
PROFILE 62 MERIDIAN MEDICAL TECHNOLOGIES
PROFILE 63 MINIMED
PROFILE 64 ML Laboratories
PROFILE 65 Nastech
PROFILE 66 NEOPHARM
PROFILE 67 NEUROTECH
PROFILE 68 NexMed
PROFILE 69 NOBEX
PROFILE 70 NOVAVAX
PROFILE 71 NOVEN PHARMACEUTICALS
PROFILE 72 OCULEX PHARMACEUTICALS
PROFILE 73 Penwest
PROFILE 74 PERIO PRODUCTS
PROFILE 75 Permatec
PROFILE 76 PHAETON RESEARCH
PROFILE 77 Pharmos
PROFILE 78 Phogen
PROFILE 79 POWDERJECT PHARMACEUTICALS
PROFILE 80 PROFILE THERAPEUTICS
PROFILE 81 Pronova
PROFILE 82 PROTEIN POLYMER TECHNOLOGIES
PROFILE 83 QUADRANT HEALTHCARE
PROFILE 84 RP SCHERER
PROFILE 85 RTP Pharma
PROFILE 86 SHEFFIELD PHARMACEUTICALS
PROFILE 87 SHIRE PHARMACEUTICALS
PROFILE 88 SKYEPHARMA
PROFILE 89 Solgene
PROFILE 90 SONUS Pharmaceuticals
PROFILE 91 SOUTHERN BIOSYSTEMS
PROFILE 92 SYNT:EM
PROFILE 93 Unigene
PROFILE 94 Valentis
PROFILE 95 VICAL
PROFILE 96 VISIONARY MEDICAL PRODUCTS
PROFILE 97 VIVUS
PROFILE 98 WATSON LABORATORIES
PROFILE 99 WEST PHARMACEUTICAL SERVICES
PROFILE 100 WESTON MEDICAL GROUP
PROFILE 101 YAMANOUCHI PHARMA TECHNOLOGIES
PROFILE 102 ZENTRX
APPENDIX 1 INDEX OF ROUTES OF ADMINISTRATION
APPENDIX 2 INDEX OF DRUG DELIVERY SYSTEMS AND PRODUCTS
APPENDIX 3 COMPANY ADDRESSES

FOREWORD

F.1 Why drug delivery?
Drug delivery techniques were established to deliver or control the amount, rate and, sometimes, location of a drug in the body to optimise its therapeutic effect, convenience and dose. Developing a well established formulation of a drug with a new delivery system is a relatively low risk activity and can be used to enhance a company's product portfolio by extending the drug's commercial life-cycle. New, therapeutic biological drugs may also depend on a novel technology to enable them to reach their target within the body. Any drug delivery system that: results in reduced side effects; is simple to use (ie does not require administration by a trained professional); is pain-free; is pleasant tasting; and is infrequent in its dosing schedule, will increase patients' quality of life meaning that more patients are likely to use it and respond to the treatment. Likewise, a promising product in vitro will have limited success in vivo and on the market if it cannot: be delivered into the body with proven high bioavailability, high absorption by the body; be effective in small enough doses that cause minimal side effects; manufactured simply and cost-efficiently; and be tailored to the needs of the disease type being treated or prevented.

F.2 Scope and methodology
Scrip's Drug Delivery Companies Fact File has been compiled largely from first-hand information from the companies profiled and from conferences such as Exploring the Rapidly Developing Area of Nasal Drug Delivery, 23–24 March 2000, Guildford, UK; the World Millennial Congress on Pharmaceuticals Sciences, 16–20 April 2000, San Francisco, US; and Investing in Biotechnology, 10 May 2000, London, UK. The Fact File includes over 100 major drug delivery companies and smaller start-ups with novel, innovative and promising technologies. Each company profile provides (if applicable) company contact details, a brief background, a financial summary, a detailed description of the drug technology platforms in development, a summary of patent status, a product pipeline table, a table of leading marketed products, a table of collaborations and licensing agreements, a list of senior executives, and licensing contact details. It is not appropriate for this first edition of the Fact File to follow the development of products and their technologies through clinical trials or to assess the market for individual areas. Furthermore, a detailed review of the developments will form the basis of a complementary report to be published in 2001– Drug Delivery Technologies: Innovations and market challenges (Isherwood, 2001).

F.3 The market for drug delivery
Drug delivery is a rapidly expanding subsection of the market for therapeutic drugs. The company MediJect estimates the current global drug delivery market to be worth $20 billion. According to SkyePharma, the world drug delivery routes are broken down as shown in Figure F.1.

Figure F.1: Breakdown of the world drug delivery routes
Source: SkyePharma.
Drug delivery is the fastest growing healthcare sector, currently growing at a rate twice that of pharmaceuticals (Drayson, 2000). Drug delivery industry sales are expected to increase at an annual rate of 15%, and this growth is thought likely to be sustained throughout the 21st century (Erickson, 2000). The worldwide vaccine market is currently $4 billion and is expected to grow to over $7 billion by 2003. There are, therefore, significant opportunities here for alternative treatments to injections (Elan Annual Report 1999). The US drug delivery market is projected to grow from $14.3 billion in 1998 to $24 billion in 2003. In the US alone it is estimated that by 2005, 20% of pharmaceutical expenditure will be used on products using drug delivery technologies (ZENTRx homepage, www.zentrx.com).

F.3.1 Current marker drivers
Over the past 10 years there has been an increase in R&D into drug delivery technologies. This growth has been, and will continue to be, fueled by a number of factors:

Controlling overall healthcare costs – the cost of developing and launching a new chemical entity (NCE) can be $300–600 million, whereas the reformulation of an existing product may cost only $50 million and still achieve peak sales of $100–200 million (Scrip Magazine May 2000)

Enhancing a product's life-cycle – pharmaceutical companies need to enhance older products reaching the end of their commercial life-cycle in order to optimise the company portfolio and maintain sales against competition. For example, according to the company Lipocine, 'line extension opportunities for oral lipid-based products worth $15 billion will become available when patents on high-selling, poorly water-soluble drugs expire over the next few decades'

Improving patient compliance – this can be achieved by improving the choice of delivery system with pain-free, pleasant tasting, convenient alternatives. Patients are also more likely to take a drug which has reduced side effects and which works quickly

Rapid growth in the worldwide biotechnology industry – this has increased drug discovery and subsequently resulted in promising compounds such as proteins, peptides, hormones and therapeutic biologicals which do not penetrate the body easily

The need to reduce side effects – this has lead to the development of drug delivery systems targeted to, for example, the colon, the brain or the location of a tumour so that treatment is localised and systemic side effects can be reduced

The need to deliver peptides and proteins – there is a demand for an alternative delivery system to injectable or infusion-delivered insulin for the estimated 18 million sufferers of Type 1 diabetes worldwide. A growing number of the 15 million Type 2 sufferers worldwide are also now administering insulin themselves. Although needle-free systems have improved delivery, researchers are focusing on non-invasive treatments that can be inhaled or taken orally. Again, according to Lipocine: 'the delivery of insulin [alone] represents a potentially large market . . . at present, as a whole, peptide and protein pharmaceuticals is worth approximately $10 billion worldwide and is expected to increase two to three times over the next decade'

Developments in nanotechnology – nanotechnology has sought to overcome solubility problems, for example by exponentially increasing the surface area of the drug exposed to the solvent. This can lead to increased bioavailibility of the drug and hence improved efficacy